Founded in 2014, Innogen is a science-driven biopharmaceutical company dedicated to the research and development of innovative and affordable medicines for metabolic disease patients. Innogen’s pipelines with indications in metabolic diseases including diabetes, obesity, MASH. are all independently developed and have global rights. Innogen has laid out global research and development and market sales.

The company's first pipeline product, Efsubaglutide Alfa (previously named as Supaglutide, with trade name: DiabegoneTM ), was approved by the NMPA in January, 2025. It is the first humanized long-acting GLP-1 drug that originated from China, which will benefit more diabetes patients. Other indications for Efsubaglutide Alfa such as obesity and MASH are also under development to address the large unmet therapeutic needs in these disease areas.

Innogen R&D team is composed of scientists and clinicians with countless years of experience in innovative drug discovery and development. Dr. Qinghua Wang, the company’s founder, chairman of the board and inventor of Efsubaglutide Alfa, is the distinguished professor of Fudan University, and project manager for Major National Science and Technology Projects for New Drug Development under the National 13th Five-Year Plans. Dr. Wang was a tenured professor at the University of Toronto and a standing committee member of the world-leading Banting Best Diabetes Center.

Innogen’s technology and production capacity of genetically engineered recombinant protein biopharmaceuticals is in line with international standards which enabled continuous drug discovery and development.

In August 2025, Innogen stock was listed on the Main Board of the Hong Kong Stock Exchange (HK.02591).